

Merck Sharp & Dohme B.V.
 Waardenweg 39
 2031 BN Haarlem
 Postbus 581
 2003 PC Haarlem
 The Netherlands
 T +31 [REDACTED] 5.1.2e
 F +31 [REDACTED]
 Email: info@msd.nl
 Website: www.msd.nl



Call with Prime Minister Rutte and VPM de Jonge: 15.30-16.00 Thursday 13th August

Meeting Participants:

[REDACTED] 5.1.2e

Meeting Purpose

- To re-engage the Dutch government on plans for our V590 and V591 COVID-19 vaccines manufacturing footprint in Europe and to share our timelines and areas of focus
- To understand the Dutch government's interest in supporting local manufacturing and the associated mechanisms and processes for securing support.

Background

- Following your call with our [REDACTED] 5.1.2e and subsequent local level constructive discussions between MSD and the Ministry of Health, Wellbeing & Sport (VWS) & Dutch European Commission negotiation team representatives. We look forward to sharing our progress with you.
- We have recently completed our global COVID-19 vaccine manufacturing planning and have identified associated resource needs for scaling up manufacturing capacity to execute this plan.
- We are now ready to re-engage to explore opportunities for support to realize this capacity expansion as rapidly as possible. Recognizing that building new facilities can take years, we are planning to build on our existing European manufacturing footprint to accelerate capacity expansion. We plan to retrofit an existing plant in Boxmeer to support manufacturing for both of our vaccine candidates, V590 and V591. We have already begun activities to expand capacity at Boxmeer with the objective to deliver millions of doses of any future licensed COVID-19 vaccines for Europe and other geographies.
- We are interested in understanding opportunities to secure funding from the Netherlands to reduce the financial impact of the at-risk investments that we are making now and will continue to make in order to provide global access to V590 and V591.

Local Contact:

[REDACTED] 5.1.2e

[REDACTED] 5.1.2e

[REDACTED] 5.1.2e

[REDACTED] [@merck.com](mailto:[REDACTED]@merck.com) +31

[REDACTED] 5.1.2e